Fixed combinations of medications that lower intraocular pressure (IOP) are increasingly
used in the treatment of glaucoma and ocular hypertension and offer several potential …

Introduction: Several large, randomized, prospective clinical trials have demonstrated that
medical therapy to reduce intraocular pressure (IOP) delays the onset and decreases …

ABSTRACT Introduction Fixed dose combinations (FCs) represent a potentially valuable
treatment strategy in glaucoma management. Fixed combinations not only improve …

Ocular hypotensive agents are the only approved pharmacotherapy for glaucoma. Despite
significant advances during the past two decades, a large proportion of glaucoma patients …

Glaucoma is a leading cause of irreversible visual loss. This potentially blinding disease is a
progressive optic neuropathy associated with elevated intraocular pressure (IOP). Initial …

Intraocular pressure (IOP) reduction is currently the only therapeutic approach demonstrated
to preserve visual function in patients with glaucoma. The first line of glaucoma treatment …

Background The first goal of medical therapy in glaucoma is to reduce intraocular pressure
(IOP), and the fixed-combination medications are needed to achieve sufficiently low target …

The main first-line treatment strategy for glaucoma is to reduce intraocular pressure (IOP) by
topical ocular hypotensive medications, but many patients require multiple medications for …

Background Fixed-combination ocular hypotensives have multiple advantages, but triple-
therapy dorzolamide/brimonidine/timolol (dorz/brim/tim) is only available in Latin and South …

In the 21st century there are more highly effective medical management options for
glaucoma than there were in the 1980s and 1990s. In deciding among them, the clinician's …